Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.49 |
| ▸ | GHSR | Q92847 | 15/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2081445 | 0.91 | ESR2 (0.49) | ESR2GHSRESR1 | |
| SCHEMBL3294838 | 0.88 | ESR2 (0.52) | ESR2GHSRNR1H2 | |
| SCHEMBL3604525 | 0.88 | GHSR (0.50) | ESR2GHSR | |
| SCHEMBL3993278 | 0.86 | ESR2 (0.44) | ESR2GHSRESR1NR1H2 | |
| SCHEMBL7511979 | 0.85 | ESR2 (0.54) | ESR2GHSRESR1NR1H2 | |
| SCHEMBL25895663 | 0.83 | GHSR (0.46) | GHSRNR1H2 | |
| SCHEMBL1201049 | 0.83 | SMN1; SMN2 (0.48) | GHSRMEN1KMT2A | |
| SCHEMBL17391023 | 0.81 | GHSR (0.47) | GHSR | |
| SCHEMBL17391179 | 0.81 | GHSR (0.46) | GHSRNR1H2MEN1KMT2A | |
| SCHEMBL17833756 | 0.81 | GHSR (0.39) | GHSRNR1H2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557123-B2 | Heterocyclic compound and medicinal use thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-6872732-B2 | Heterocyclic derivatives and medicinal use thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2005-03-29 | — | — | US | disclosed |
| US-20040220215-A1 | Novel heterocyclic compound and medicinal use thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2004-11-04 | — | — | US | disclosed |
| US-20040180924-A1 | Novel heterocyclic derivatives and medicinal use thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1403253-A1 | NOVEL HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1398313-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2004-03-17 | — | — | EP | disclosed |
| US-6589963-B2 | Drug salt thereof show a hypoglycemic action, a blood hypolipidemic action, an insulin resistance-improving action and a PPAR activating action, and are useful as a hypoglycemic agent, a hypolipidemic agent, an insulin | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2003-07-08 | — | — | US | disclosed |
| US-20030027836-A1 | Novel heterocyclic compounds and salts thereof and medicinal use of the same | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2003-02-06 | — | — | US | disclosed |
| EP-1236719-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND SALTS THEREOF AND MEDICINAL USE OF THE SAME | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027836-A1 | Novel heterocyclic compounds and salts thereof and medicinal use of the same | GPR119, PPARA, PPARG | ESR2 311/4885GHSR 29/4885ESR1 655/4885 |
| US-20040180924-A1 | Novel heterocyclic derivatives and medicinal use thereof | GPR119, INSR, GLP1R | ESR2 890/4885GHSR 27/4885ESR1 1002/4885 |
| US-20040220215-A1 | Novel heterocyclic compound and medicinal use thereof | GPR119, INSR, GLP1R | ESR2 1319/4885GHSR 26/4885ESR1 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.